A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.